Monitor upcoming clinical data releases in 2026 for vispa-cel and CB-011, which could be catalysts. Watch for financing activities as the company explores options to fully fund the vispa-cel pivotal trial despite current cash runway into 2H 2027.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 6 $1.82entry
- T+1 · 8mo ago +8.24%α +7.40% · $1.97
- T+5 · 8mo ago +3.30%α +4.83% · $1.88
- T+20 · 8mo ago +7.14%α +9.19% · $1.95
- T+60 · 6mo ago +33.52%α +20.74% · $2.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Caribou Biosciences reported its 2025 financial results, showing a slight improvement in net loss despite a $21.3M non-cash impairment charge. The company highlighted positive clinical data for its allogeneic CAR-T therapies vispa-cel and CB-011, with longer-term data expected in 2026. Cash reserves decreased to $142.8M but are expected to fund operations into 2H 2027.
Key Financial Metrics
Key Facts
- Licensing revenue increased to $11.2M in 2025 from $10.0M in 2024
- R&D expenses decreased to $109.4M in 2025 from $130.2M in 2024
- GAAP net loss was $148.1M in 2025 vs $149.1M in 2024
- Non-GAAP net loss improved to $126.8M in 2025 from $149.1M in 2024
- Cash, cash equivalents, and marketable securities decreased to $142.8M from $249.4M
- Company expects current cash to fund operations into 2H 2027
- Presented positive clinical data for vispa-cel and CB-011 at Tandem Meetings
- Engaging with FDA on pivotal trial design for vispa-cel in 2L LBCL
Financial Impact
Net loss decreased by $1M YoY despite $21.3M impairment charge, with cash burn of $106.6M for the year
Risk Factors
- Significant cash burn with $106.6M used in 2025
- Need for additional funding to fully support pivotal trial for vispa-cel
- Clinical trial risks and regulatory approval uncertainties
- Recent insider selling of $47K in the past 30 days
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001619856-26-000007 |
| Document: crbu-20260305.htm | 0001619856-26-000007 |
| Document: 0001619856-26-000007-index-headers.html | 0001619856-26-000007 |
| Document: 0001619856-26-000007-index.html | 0001619856-26-000007 |
| Document: 0001619856-26-000007.txt | 0001619856-26-000007 |
Track record
13 reports on CRBU
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Viewing Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers